The approach to more selectivity

TheraSorb™ Therapeutic Apheresis is based on the selective removal of pathogenic substances from the
patient’s plasma. During apheresis, target molecules are selectively removed from the plasma which is
then recombined with the cellular components and reinfused into the patient. Hence, higher plasma
volumes can be processed than in therapeutic plasma exchange. Since no substitution fl uid is
required, the treatment is usually very well tolerated.

Different adsorbers in the TheraSorb Product Line can be used to selectively remove either undesired
immunoglobulins, low-density lipoprotein (LDL), and lipoprotein (a) (Lp(a)), or fi brinogen and fi brin
degradation products. These features may be helpful for the treatment of diseases associated with
pathogenic immunoglobulins, hypercholesterolemia, microcirculation impairment, and fi brinogen..